D&D PHARMATECH
D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases, providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients.
D&D PHARMATECH
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Status:
Active
Total Funding:
224.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apache Mobile Non Scaleable Content Google Apps For Business Google Maps Google Maps API Sectigo SSL
Similar Organizations
FAB Pharmaceuticals
FAB Pharmaceuticals is a Health Care Company.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Pearl Care
Pearl Care is Healthcare company.
Pharmate
Pharmate is a health care company.
StanPlus
A Health And Healthcare Company.
Trinomab
Trinomab is a Healthcare company.
Current Employees Featured
Founder
Investors List
DS Asset Management
DS Asset Management investment in Series C - D&D Pharmatech
Praxis Capital Partners
Praxis Capital Partners investment in Series C - D&D Pharmatech
Korea Investment Securities
Korea Investment Securities investment in Series C - D&D Pharmatech
Kudos Venture Capital
Kudos Venture Capital investment in Series C - D&D Pharmatech
Magna Investment
Magna Investment investment in Series B - D&D Pharmatech
InterVest Co.
InterVest Co. investment in Series B - D&D Pharmatech
Octave Life Sciences
Octave Life Sciences investment in Series B - D&D Pharmatech
LB Investment
LB Investment investment in Series B - D&D Pharmatech
Smilegate Investment
Smilegate Investment investment in Series B - D&D Pharmatech
LB Investment
LB Investment investment in Series A - D&D Pharmatech
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-07-18 | Neuraly | D&D Pharmatech investment in Series A - Neuraly | 36 M USD |
More informations about "D&D Pharmatech"
D&D Pharmatech Inc. - MarketScreener.com
Aug 21, 2024 Certain Common Stock of D&D Pharmatech Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. May. 24: CI Certain Common Stock of D&D Pharmatech …See details»
D&D Pharmatech - Funding, Financials, Valuation & Investors
D&D Pharmatech is registered under the ticker KOSDAQ:347850 . Their stock opened with â‚©33,000.00 in its Apr 24, 2024 IPO. D&D Pharmatech is funded by 13 investors. DS Asset …See details»
D&D Pharmatech Company Profile 2024: Stock Performance
Jul 18, 2018 D&D Pharmatech General Information Description. D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and …See details»
D&D Pharmatech Granted Fast Track Designation from US FDA for …
Apr 3, 2024 About D&D Pharmatech. ... CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected …See details»
Ahead of IPO, D&D Pharmatech wins US fast track for MASH drug
Apr 4, 2024 Building D&D Pharmatech Inc. has been a rollercoaster ride, according to CEO Seulki Lee. The U.S. and Korea-based biotech is on another ascent, having scored U.S. FDA …See details»
D&D Pharmatech - Craft
D&D Pharmatech is a clinical-stage biological technology company. The company runs its global product development operations via multiple partnerships and owns subsidiaries focused on …See details»
D&D Pharmatech - VentureRadar
" D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided …See details»
D&D Pharmatech Raises $51M in Series C Financing to Advance
Oct 19, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharmatech Raises $51M in Series C Financing to …
Oct 19, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical ...See details»
D&D Pharmatech Raises $51M in Series C Financing to Advance …
Oct 19, 2021 GYEONGGI-DO, Korea & GAITHERSBURG, Md.– D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of …See details»
D&D Pharmatech Raises $137.1M in Series B Financing to Advance ...
Aug 14, 2019 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharma snags $51M ahead of Korean IPO for Alzheimer's, …
Oct 19, 2021 D&D Pharmatech has secured. Aside from Neuraly, Korea-based D&D owns U.S. subsidiaries Precision Molecular, Theraly Fibrosis, P4Microbiome and Valted Seq. D&D's last …See details»
D&D Pharmatech Announces Rapid, Clinically Significant …
May 2, 2023 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials
Aug 14, 2019 D&D Pharmatech has raised $137.1 million to advance treatments for neurodegenerative diseases and fibrosis. The series B will enable one D&D subsidiary to run …See details»
Culturally Nimble CEO Ready to Lead D&D Pharmatech
Jul 6, 2021 Yoo-Seok Hong, the newly-appointed CEO of D&D Pharmatech, has moved between South Korea and North America eight times. In one two-year period, he amassed one …See details»
D&D Pharmatech Announces First Patient Dosed in Phase 1 …
Mar 30, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
D&D Pharmatech closes $51M series C round, eyes Seoul IPO
Oct 19, 2021 D&D Pharmatech Inc., a Korean-American firm commercializing innovation from Johns Hopkins University (JHU) raised $51 million in a pre-IPO series C round, which sets the …See details»
D&D Pharmatech Announces Agreement with Salubris …
Sep 27, 2021 D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies …See details»
DD-01 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 About D&D Pharmatech D&D Pharmatech is a clinical-stage biopharmaceutical company focused on developing evolutionary medicines for treating patients with metabolic, …See details»